Ira Fine, MD
Rheumatology · Lutherville, MDNPI 1922079599
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,088, more than ten times the $19 reported in 2019. That places this record below the midpoint for rheumatology clinicians in MD, where the typical reported total is $2,316.
Across 114 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$426
- Pfizer$373
- Novartis$362
- Amgen$252
- Johnson & Johnson$163
- Fresenius Kabi USA, LLC$149
- plus $931 from 17 others
What the payments were for
- Food & beverage$2,63599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 21 | $426 |
| Pfizer | 18 | $373 |
| Novartis | 12 | $362 |
| Amgen | 11 | $252 |
| Johnson & Johnson | 8 | $163 |
| Fresenius Kabi USA, LLC | 5 | $149 |
| Aurinia Pharma U.S., Inc. | 5 | $139 |
| E.r. Squibb & Sons, L.L.C. | 7 | $138 |
| Sandoz | 3 | $88 |
| Sobi, Inc | 3 | $73 |
| Genentech USA, Inc. | 4 | $67 |
| AbbVie | 2 | $59 |
| Merck | 2 | $59 |
| Biocon Biologics Inc | 2 | $52 |
| AstraZeneca | 2 | $43 |
| Organon | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| GSK | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Corcept Therapeutics | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
How this compares
$2,655 in reported general payments places this provider in the 50th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 13 | $91,186 |
| HumiraAdalimumab | 13 | $86,397 |
| EliquisApixaban | 61 | $69,014 |
| Actemra ActpenTocilizumab | 11 | $51,950 |
| OzempicSemaglutide | 24 | $25,438 |
| XareltoRivaroxaban | 26 | $24,535 |
| MyrbetriqMirabegron | 25 | $13,957 |
| JanuviaSitagliptin Phosphate | 14 | $13,878 |
| TrulicityDulaglutide | 13 | $12,499 |
| SynthroidLevothyroxine Sodium | 66 | $5,398 |
| Atorvastatin Calcium | 322 | $5,033 |
| Rosuvastatin Calcium | 176 | $3,508 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 16 | $3,501 |
| Valsartan | 98 | $3,439 |
| Levothyroxine Sodium | 148 | $3,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Synthroid | $59 | $91,79579 claims |
| PfizerEliquis, Paxlovid | $373 | $70,443100 claims |
| Johnson & JohnsonXarelto | $163 | $24,53526 claims |
| MerckJanuvia | $59 | $13,87814 claims |
| GSKShingrix | $31 | $3,50116 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $35 | $3,43998 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 173 rheumatology providers in Maryland.
Other rheumatology in Lutherville
- Marisa MizusLutherville$104K
- Susanna JeurlingLutherville$27K
- Evan SiegelRockville$594K
- Donald ThomasGreenbelt$471K
- Edmund MaclaughlinEaston$410K
- Michelle PetriBaltimore$381K
- Herbert BarafWheaton$268K
- Elizabeth ClaytonEaston$244K
- Alan MatsumotoWheaton$185K
- Nasser NasseriaslCatonsville$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.